Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration
Journal
Journal of the Chinese Medical Association : JCMA
Journal Volume
78
Journal Issue
11
Date Issued
2015-11
Author(s)
Lin, Tai-Chi
Hung, Kuo-Hsuan
Peng, Chi-Hsien
Liu, Jorn-Hon
Tsai, Ching-Yao
Chen, Shih-Jen
Chen, Yan-Ting
Hsu, Chih-Chien
Abstract
Nanoparticles combined with cells, drugs, and specially designed genes provide improved therapeutic efficacy in studies and clinical setting, demonstrating a new era of treatment strategy, especially in retinal diseases. Nanotechnology-based drugs can provide an essential platform for sustaining, releasing and a specific targeting design to treat retinal diseases. Poly-lactic-co-glycolic acid is the most widely used biocompatible and biodegradable polymer approved by the Food and Drug Administration. Many studies have attempted to develop special devices for delivering small-molecule drugs, proteins, and other macromolecules consistently and slowly. In this article, we first review current progress in the treatment of age-related macular degeneration. Then, we discuss the function of vascular endothelial growth factor (VEGF) and the pharmacological effects of anti-VEGF-A antibodies and soluble or modified VEGF receptors. Lastly, we summarize the combination of antiangiogenic therapy and nanomedicines, and review current potential targeting therapy in age-related macular degeneration.
Subjects
age-related macular degeneration; choroidal neovascularization; nanotechnology; target therapy; vascular endothelial growth factor
Type
review